Trinity Biosystems raises $7.5M bridge to treat endocrine disorders
Trinity Biosystems, maker of a drug that can treat certain endocrine disorders, has brought in $7.5 million in bridge funding from Amgen Ventures, Life Science Partners, Lilly Ventures, Sanderling Ventures and SR One, according to Dow Jones VentureWire. Based in Menlo Park, Calif., the company has raised about $33.75 million since its first round of financing in 2004.
Life-science briefing: Friday, April 11, 2008
TODAY’S HEADLINES:
Stent maker IDev Tech raises $25M (VentureWire)
Xytis gets $15M for brain-injury drugs (VentureWire)
Diagnostic maker Iris Biotech plans to go public, launch breast-cancer test (Edgar)
RiverVest Venture Partners raises $75M life-science fund (release)
Concentric Medical names Maria Sainz CEO (release)
[Note: I’m a little sad to announce that this will be my last life-science briefing at VentureBeat, although with luck, it won’t be the end of my time here. Starting Monday, I’ll be blogging regularly on the drug industry and… Continue Reading
Life-science briefing: Monday, March 31, 2008
TODAY’S HEADLINES:
Boston Scientific spinout TriVascular2 takes in $65M (release)
Inhaled-drug startup Transave raises $35M (release)
Triage Wireless gets $20M for vital-signs monitors (release)
Tryton Medical receives $14M for “bifurcation” stents (release)
Synthetic bio startup Codon Devices adds $11M (release)
Tracon Pharma takes in $4.5M against cancer and eye disease (VentureWire)
Antibody maker f-star swaps in equity stake by TVM (PDF release)
Drug packager MonoSol Rx withdraws IPO (IPOhome)
GE Healthcare acquires portable-ventilator maker VersaMed (release)
Boston Scientific spinout TriVascular2 takes in $65M – In 2005, Boston… Continue Reading
Life sciences briefing: Monday, March 3 ,2008
TODAY’S HEADLINES:
InfraReDx takes $17M for arterial-plaque detection (VentureWire)
Cancer-drug developer Serenex sells out to Pfizer for undisclosed sum (release)
Life-sciences fund Longitude Capital raises $95M (VentureWire)
Hospital consultant Intercede Health names Gray Miller as CEO (release)
InfraReDx takes $17M for arterial-plaque detection – InfraReDx, a Burlington, Mass., developer of diagnostic systems that detect arterial plaque, raised $17 million in a third funding round, VentureWire reports. Sanderling Ventures led the round, joined by new and previous individual investors.
InfraReDx previously planned to… Continue Reading
Life sciences briefing: Tuesday, Feb. 12, 2008
TODAY’S HEADLINES:
Metabolic-disease biotech NGM Biopharma raises $25M (peHUB)
Heart, HIV drug maker Numerate acquires assets of Pharmix (release)
Next-gen sequencer VisiGen promises $1,000 genome by late 2009 (Genome Technology)
CalciMedica raises $5.5M for autoimmune drugs (VentureWire)
Cancer-drug e-marketplace OneOncology raises funds (release)
U.K. biotech Hunter-Fleming acquired by Newron for €8M (release)
Intertek acquires Ireland’s Bioclin Labs, a contract research organization (release)
Metabolic-disease biotech NGM Biopharma raises $25M – South San Francisco-based NGM Biopharmaceuticals (Web site under construction), a biotech developing new drugs for… Continue Reading
Life sciences briefing: Friday, Feb. 1, 2008
TODAY’S HEADLINES:
Taligen Therapeutics raises $65M for novel anti-inflammatory drugs (release)
Dental-implant maker Biohorizons acquires Implant Logic (release)
MAKO Surgical sets IPO terms, seeks $94M for knee implants and robots (Edgar)
Canada’s Medical Ventures acquires two Israeli device startups (release)
CRO Chiltern acquires Drug Development Solutions (release)
Taligen Therapeutics raises $65M for novel anti-inflammatory drugs –Aurora, Colo.-based Taligen Therapeutics, a biotech working on targeted anti-inflammatory drugs, raised $65 million in a second round of funding. The deal is one of the… Continue Reading
Life sciences briefing: Thursday, Dec. 6, 2007
(UPDATED: Expanded items on LineaGen, BG Medicine. Pelikan Tech is described in a standalone item here.)
TODAY’S HEADLINES:
Pelikan Tech raises $69M for diabetes glucose tests (release)
Utah’s LineaGen draws $6M for genetic diagnostics (VentureWire, sub req’d)
Beijing’s IKang Healthcare gets $25M for medical-service centers (VW)
BG Medicine drops IPO price range, seeks up to $52M (Edgar)
Sepragen completes acquisition of Cyto Biologic Tech (release)
Utah’s LineaGen draws $6M for genetic diagnostics — LineaGen (no Web site), a Salt Lake City biotech focused… Continue Reading
Novocell: With diabetes study pending, investors pony up another $25M
Novocell, a San Diego embryonic stem-cell company, raised $25 million in a third round of funding. That’s presumably a bit of a letdown for the company, which had previously hoped to pull in as much as $35 million in the round. I wrote earlier about Novocell’s fundraising here.
The round was led by Johnson & Johnson Development, the venture arm of J&J itself, joined by Sanderling Ventures, Asset Management Company and Pacific Horizon Ventures.
In my… Continue Reading
NeoMend pulls together $6M for wound healing
NeoMend, an Irvine, Calif., biomaterials company focused on wound care, raised $6 million in a third funding round, VentureWire reports (subscription required). Investors included Prospect Venture Partners, Sanderling Ventures and other unidentified venture capitalists. Four million dollars in bridge loans from Prospect and Sanderling also converted into equity.
NeoMend is developing an adhesive gel it calls Pro/PEG that can be sprayed or injected into surgical or other wounds to close them up. The company said the… Continue Reading
TheraVida raises seed funding for urology research
TheraVida, a new biotech based in San Mateo, Calif., has raised seed funding from Sanderling Ventures, VentureWire reports (subscription required). The company, which doesn’t seem to have a Web site (a possible stub site is here), is researching possible drugs for urological problems.
According to VentureWire, the seed funding was less than $1 million, although the company may seek a larger first funding round by the end of the year. TheraVida has one employee, a… Continue Reading
PET scanner Naviscan pulls in $15M
Naviscan PET Systems, a San Diego maker of high-resolution positron-emission tomography (PET) scanners, raised $15 million in a third round of funding led by QuestMark Partners.
Returning investors included Sanderling Ventures, Mayo Medical Ventures and Walker Ventures. The company plans to use the new funding to continue clinical validation and commercialization of its PEM Flex Solo II PET scanner, which it claims can image tumors less than two millimeters in diameter.
Naviscan, previously based in Rockville, Md.,… Continue Reading